Anti-Human ErbB2-174Yb

Catalog: 3174021B  Clone: 42/c-erbB-2
Package Size: 100 tests  Isotype: Mouse IgG2b
Storage: Store product at 4°C. Do not freeze.  Formulation: Antibody stabilizer with 0.05% Sodium Azide
Reactivity: Human

Technical Information

Validation: Each lot of conjugated antibody is quality control tested by CyTOF® analysis of stained cells using the appropriate positive and negative cell staining and/or activation controls.

Recommended Usage: The suggested use is 1 µl for up to 3 X 10^6 live cells in 100 µl. It is recommended that the antibody be titrated for optimal performance for each of the desired applications.

Description

ErbB2 (also known as HER2/Neu) is the most potent oncogene among the epidermal growth factor receptor family. Although ErbB2 does not bind a ligand, it is constantly prone to dimerization and recruits the largest group of phosphotyrosine-binding proteins among all ERBB members. The ErbB2 gene is located on chromosome 17 (C17) and is amplified and overexpressed in about 20-30% of cases of primary human breast cancer, correlating with adverse patient outcome. ErbB2 overexpression impacts on various cancer cell-associated phenotypes including resistance to apoptosis, hyperproliferation, increased motility and constitutive activation of the PI3K/AKT pathway. Moreover, ErbB2-containing heterodimers are the most potent ErbB complexes as they show higher growth factor affinities, undergo slow endocytosis and are constantly re-cycled to the cell membrane. On the other hand, ErbB2 function has also been implicated in physiological processes such as heart or oligodendrocyte development.

References


For technical support visit fluidigm.com/support

For Research Use Only. Not for use in diagnostic procedures.

Information in this publication is subject to change without notice. Safety data sheet information fluidigm.com/sds Patent and license information fluidigm.com/legalnotices | Fluidigm, the Fluidigm logo, and CyTOF are trademarks or registered trademarks of Fluidigm Corporation in the United States and/or other countries. © 2015 Fluidigm Corporation. All rights reserved. 07/2015